An investigation for investors in Portola Pharmaceuticals Inc (NASDAQ:PTLA) shares over potential securities laws violations was announced and NASDAQ:PTLA stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 04/22/2016 -- An investigation for shareholders of Portola Pharmaceuticals Inc (NASDAQ:PTLA) was announced over potential securities laws violations in connection certain financial statements.
Investors who purchased shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Portola Pharmaceuticals Inc (NASDAQ:PTLA) concerning whether certain statements regarding by Portola Pharmaceuticals' business, its prospects and its operations were materially false and misleading at the time they were made.
On March 24, 2016 Portola Pharmaceuticals Inc announced data from the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study, which evaluated the superiority of extended-duration anticoagulation with oral betrixaban compared with standard of care anticoagulation with injectable enoxaparin for the prevention of venous thromboembolism (VTE), or blood clots, in acute medically ill patients. Shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA0 declined to as low as $18.20 per share on March 28, 2016.
On April 20, 2016, NASDAQ:PTLA shares closed at $25.06 per share.
Those who purchased shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com